Pharmacy
Affordable Care Act's fate is coming into question as healthcare organizations move into the new world of value-based care and other advances.
Canadian drugmaker Valeant Pharmaceuticals International Inc. acquired the medication in February 2015 and abruptly doubled the $1,500 retail price.
Five of the six drugs with the highest cumulative price increases over the study period were marketed by Valeant Pharmaceuticals.
And as many are now doing, the company is currently awaiting what will happen to the healthcare landscape under a new presidential administration.
The increase comes on the heels of a five-year period of historically low growth, from 2009 to 2013.
A massive lobbying effort by 58 pharmaceutical companies, 24 device companies and 26 "biotech products and research" companies shaped the bill.
More than 1,455 lobbyists representing 400 companies, universities and other organizations pushed for or against a House version of a Cures bill this congressional cycle.
Prices for outpatient, inpatient, professional services, and prescription drugs increased between 3.5 and 9 percent in 2015, report says.
Using its claims data and analytics, Cigna will alert these doctors when their opioid prescribing patterns are not consistent with CDC guidelines.
Nermin Awad El-Hadik colluded with a Texas clinic manager for referrals, many who required pricey compound medications.